Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.50 |
| ▸ | ITGAL | P20701 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 2/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450831 | 1.00 | ITGB2 (0.50) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL338807 | 0.87 | ITGB2 (0.46) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL158579 | 0.76 | — | — | |
| SCHEMBL1593140 | 0.72 | MAOA (0.45) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL9584128 | 0.71 | ALDH1A1 (0.44) | SMN1; SMN2LMNAGAAPKM | |
| SCHEMBL577551 | 0.71 | FABP6 (0.40) | SMN1; SMN2PKMMAOAMAOB | |
| SCHEMBL9585550 | 0.71 | FABP6 (0.40) | SMN1; SMN2PKMMAOAMAOB | |
| SCHEMBL7298481 | 0.71 | MAP3K14 (0.42) | MAOB | |
| SCHEMBL1593196 | 0.71 | PKM (0.47) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL7298128 | 0.71 | MAP3K14 (0.42) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793559-A1 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | claimed |
| CN-112469412-A | Substituted dihydropyrazolopyrazine carboxamide derivatives | 拜耳公司 | 2021-03-09 | — | — | CN | claimed |
| US-20140357655-A1 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | claimed |
| EP-2804867-A1 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS | Bayer Intellectual Property GmbH (DE) | 2014-11-26 | — | — | EP | claimed |
| WO-2013107743-A1 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | WO | claimed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | claimed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | claimed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | claimed |
| EP-2134678-A2 | N-(5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | claimed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2004033632-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | claimed |
| WO-2004032846-A2 | TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040067996-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-08 | — | — | US | claimed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | claimed |
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | claimed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | claimed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | claimed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | UNG, IDUA, TNF | ITGB2 4037/4885ICAM1 2085/4885ITGAL 2281/4885 |
| US-20040067996-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, ADAMTS1 | ITGB2 3823/4885ICAM1 787/4885ITGAL 1693/4885 |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | ITGB2 861/4885ICAM1 965/4885ITGAL 748/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | ITGB2 2807/4885ICAM1 970/4885ITGAL 2129/4885 |
| US-20140357655-A1 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS | GNRHR, FSHR, NR5A1 | ITGB2 4388/4885ICAM1 4506/4885ITGAL 3461/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | ITGB2 3021/4885ICAM1 1092/4885ITGAL 2513/4885 |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | ITGB2 3288/4885ICAM1 1197/4885ITGAL 2395/4885 |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | ITGB2 3914/4885ICAM1 1154/4885ITGAL 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.